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The E2 glycoprotein of hepatitis C virus (HCV) mediates viral attachment and entry into target hepatocytes
and elicits neutralizing antibodies in infected patients. To characterize the structural and functional basis of
HCV neutralization, we generated a novel panel of 78 monoclonal antibodies (MAbs) against E2 proteins from
genotype 1a and 2a HCV strains. Using high-throughput focus-forming reduction or luciferase-based neutral-
ization assays with chimeric infectious HCV containing structural proteins from both genotypes, we defined
eight MAbs that significantly inhibited infection of the homologous HCV strain in cell culture. Two of these
bound E2 proteins from strains representative of HCV genotypes 1 to 6, and one of these MAbs, H77.39,
neutralized infection of strains from five of these genotypes. The three most potent neutralizing MAbs in our
panel, H77.16, H77.39, and J6.36, inhibited infection at an early postattachment step. Receptor binding studies
demonstrated that H77.39 inhibited binding of soluble E2 protein to both CD81 and SR-B1, J6.36 blocked
attachment to SR-B1 and modestly reduced binding to CD81, and H77.16 blocked attachment to SR-B1 only.
Using yeast surface display, we localized epitopes for the neutralizing MAbs on the E2 protein. Two of the
strongly inhibitory MAbs, H77.16 and J6.36, showed markedly reduced binding when amino acids within
hypervariable region 1 (HVR1) and at sites 100 to 200 residues away were changed, suggesting binding to a
discontinuous epitope. Collectively, these studies help to define the structural and functional complexity of
antibodies against HCV E2 protein with neutralizing potential.
Hepatitis C virus (HCV) is a blood-borne hepatotropic virus
that infects 170 million people worldwide. Approximately
70% of infected individuals progress to chronic liver disease,
which carries an increased risk of cirrhosis and hepatocellular
carcinoma (7). In general, treatment of chronic HCV infection
is complicated by resistance due to extensive genetic diversity.
HCV has been classified into seven major genotypes, which
differ by 30% at the nucleotide level (4), and this positive-
sense, single-stranded RNA virus has a capacity for rapid
evolution of variant viruses during persistent infection. The
current treatment, pegylated 2a interferon (IFN-2a) and
ribavirin, has variable side effects and response rates depend-
ing on the virus and host genotype (16). No vaccine is currently
available, and preclinical development has been hampered by
a lack of understanding of which conserved epitopes on the
HCV structural proteins should be targeted.
HCV contains an 9.6-kb RNA genome that is translated as
a single polyprotein and then cleaved by viral and host pro-
teases into structural proteins (core, E1, and E2), p7, and
nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A, and
NS5B) (39). Viral attachment and entry are mediated by the
envelope glycoproteins, E1 and E2. Four attachment or
entry receptors that are required for infection of hepato-
cytes have been identified, including CD81 (53), scavenger
receptor B1 (SR-B1) (56), and the tight-junction proteins
claudin 1 (CLDN1) (14) and occludin (OCLN) (54). The im-
portance of E2 binding to the large extracellular loop of CD81
has been established in vitro (13, 18, 28, 50, 53), and interac-
tions between E2 hypervariable region 1 (HVR1) and SR-B1
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have been reported (3, 5, 56). The structural basis of binding of
E2 to its cognate cell attachment factors, however, is poorly
understood, in part because high-resolution structures of the
HCV glycoproteins or intact virion have not been solved.
The role of the humoral immune response in controlling
HCV infection in patients remains controversial, as patients
with persistent infection develop high-titer antibodies that do
not appear to clear infection (reviewed in reference 7). None-
theless, there are emerging data showing that classes of mono-
clonal (MAbs) and polyclonal antibodies against HCV have
protective activity. Binding to CD81 by soluble forms of E2
(sE2, truncated proximal to the transmembrane domain) is
inhibited by antibodies that also neutralize infection of pseu-
dotyped HCV particles (HCVpp) derived from the structural
proteins of multiple genotypes (1, 45). Perhaps more con-
vincing, experiments in chimpanzees and chimeric mice have
shown that passive transfer of anti-E2 antibodies protects
against infection (15, 37, 64), and immunization with E1-E2
virus-like particles (VLPs) and E2 glycoprotein in chimpanzees
induces protective antibodies (10, 29, 37). Moreover, in a com-
prehensive study of neutralizing MAbs derived from infected
patients, MAbs that bound regions comprised of amino acid
residues 396 to 424, 436 to 447, and 523 to 540 on E2
neutralized HCVpp derived from multiple genotypes (37).
Thus, anti-E2 antibodies apparently can restrict HCV infec-
tion, although the exact steps (attachment, entry, or fusion) in
the viral entry process that are inhibited and the corresponding
E2 binding epitopes have not been elucidated.
To gain more insight into the molecular and structural basis
of anti-E2 antibody neutralization of HCV infection, we gen-
erated a panel of 78 mouse MAbs against soluble, recombinant
E2 proteins derived from genotypes 1a (strain H77) and 2a
(strain J6) HCV strains. These MAbs were analyzed for inhib-
itory activity against infectious HCV in cell culture, and their
mechanisms of action with respect to inhibition of ligand bind-
ing on the cell surface were assessed. By combining this func-
tional analysis with a high-throughput yeast surface display
mapping strategy, we identified neutralizing MAbs that bound
to distinct regions of E2, including MAbs that recognized
determinants with discontinuous epitopes and with primary
sequences greater than 100 amino acids apart. These exper-
iments suggest that neutralizing MAbs blocking distinct
stages of the HCV cell entry process recognize discontinuous
epitopes on the E2 protein.
MATERIALS AND METHODS
Cells and viruses. Huh-7.5 cells were cultured in Dulbecco’s modified
Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS)
(Equitech), nonessential amino acids (Gibco), and antibiotics (penicillin G and
streptomycin) at 37°C in a 5% CO2 incubator. SF9 cells were cultured in Grace’s
insect cell medium (Gibco) supplemented with 10% FBS at 28°C. Hi-5 cells were
cultured in Ex-cell medium (Gibco) at 27°C. CHO cells were grown in Ham’s
F-12 medium (Gibco) supplemented with 10% FBS (HyClone) at 37°C.
The genotype 2 J6/JFH1/JC1 HCV chimera, which expresses luciferase (58),
was a generous gift from Apath Inc. The HJ3-5 H77/JFH1 chimera, which
expresses the core-NS2 segment of the genotype 1a polyprotein within a geno-
type 2a background, has been described previously (40, 67). The genotype 1a
H77C/JFH1(57), genotype 2a J6/JFH1 (38), genotype 3a S52/JFH1 (23), geno-
type 4a ED43/JFH1 (57), genotype 5a SA13/JFH1 (32), and genotype 6a HK6a/
JFH1 (24) infectious HCV recombinants used in cross-neutralization studies
have also been described previously. Cell culture compensatory and adaptive
mutations for the HJ3-5, S52/JFH1, ED43/JFH1, SA13/JFH1, and HK6a/JFH1
chimeras have been described previously (24, 40, 67).
To generate virus stocks from infectious cDNA clones, plasmids were linear-
ized and RNA transcription was performed using the T7 DNA-dependent RNA
polymerase (Megascript Kit; Ambion). Infectious HCV RNA (2 g) was elec-
troporated as described previously (38), and virus was harvested at 48, 72, and
96 h, sterile filtered (0.2-mm filter; Corning Inc.), and buffered with 10 mM
HEPES, pH 7.2 (Mediatech, Inc.). Virus was stored at 4°C for short-term usage,
or aliquots were prepared and stored at 80°C. Virus titration on Huh-7.5 cells
was performed by 50% tissue culture infective dose (TCID50) assay as previously
described (38).
Generation of CHO cells stably expressing HCV cell entry factors. Human
SR-B1 and CD81 genes were expressed in CHO cells via lentivirus transduction
in the context of pTRIP, a self-inactivating lentiviral provirus that expresses no
HIV proteins but instead employs an internal cytomegalovirus (CMV) promoter
to express cloned genes. An intermediate plasmid, called TRIP-GFP-linker, was
generated as a backbone into which SR-B1 and CD81 were cloned (all entry
factor templates were kindly provided by C. Rice, Rockefeller University, NY).
TRIP-GFP-linker was generated by amplifying the green fluorescent protein
(GFP) sequence with the forward oligonucleotide 5-CGC AAA TGG GCG
GTA GGC GTG and the reverse oligonucleotide 5-CTC GAG CTA GTC GAC
TTC GAA ACT AGT GCT AGC CCG CGG CTT GTA CAG CTC GTC CAT
GCC. The PCR product was digested with restriction enzymes BamHI and XhoI
and ligated into the TRIP-GFP plasmid digested with the same enzymes. The
human SR-B1 sequence was amplified with forward oligonucleotide 5-CCG
CGG ATG GGC TGC TCC GCC AAA GCG and reverse oligonucleotide
5-GCT AGC CAG TTT TGC TTC CTG CAG CAC from the previously
described TRIP-hu-SR-B1 plasmid (54) to generate TRIP-GFP-hu-SR-B1-
linker. The PCR product was digested with SacII and NheI and ligated into
similarly digested TRIP-GFP-linker. The human CD81 sequence was amplified
from an expression construct, TRIP-GFP-hu-CD81 (56), with forward oligonu-
cleotide 5-GCT AGC ATG GGA GTG GAG GGC TGC ACC and reverse
oligonucleotide 5-ACT AGT GTA CAC GGA GCT GTT CCG GAT. The PCR
product was digested with NheI and SpeI and ligated into similarly digested
TRIP-GFP-linker to generate TRIP-GFP-hu-CD81-linker.
Pseudoparticle production was performed as previously described (54) by
cotransfection of three plasmids encoding a TRIP provirus containing a trans-
gene, HIV Gag-Pol, and the vesicular stomatitis virus (VSV) G glycoprotein.
293-T cells were seeded at 1.8  106 cells/well into a poly-L-lysine (Sigma)-coated
six-well plate. Transfection was performed the next day using a total of 1.5 g of
DNA plasmid, with 6 l of TransIT-LT1 transfection reagent (Mirus). Superna-
tants were collected 24, 48, and 72 h posttransfection; filtered (0.45-m pore
size); and mixed with 100 l of 1 M HEPES buffer. All transductions were
performed in the presence of 4 g/ml Polybrene (Sigma). Receptor expression
was verified by flow cytometry using the following protocol. Cells were lifted
using phosphate-buffered saline (PBS) supplemented with 4 mM EDTA and
10% FBS, washed, and pelleted in a V-bottom plate. Cells (105) were incubated
with 20 g/ml of either mouse anti-hu-CD81 (BD Biosciences) or rabbit anti-
hu-SR-B1 (Ab-Cam) for 30 min on ice, washed, and then incubated with goat
anti-mouse IgG or goat anti-rabbit IgG secondary antibody conjugated to Alexa
Fluor 647 (Molecular Probes). The cells were washed twice, and receptor ex-
pression was analyzed on a FACSArray flow cytometer (Becton-Dickinson) using
FloJo software (Tree Star).
Cloning, expression, and purification of recombinant HCV E2. The E2 protein
ectodomain of strain H77 (amino acids [aa] 384 to 661) (35) or J6 (aa 385 to 661)
was cloned into a baculovirus expression vector (pFastBac derivative) from
plasmids containing the structural proteins of H77 (a gift from M. Gale, Jr.,
University of Washington) or the infectious J6/JFH1/JC1 (58) viral genome (a
gift from Apath, Inc.). The baculovirus expression vector adds a honeybee melit-
tin signal peptide at the NH2 terminus and a thrombin-cleavable His6 tag and
stop codon at the COOH terminus. Recombinant baculoviruses expressing HCV
E2 ectodomains were generated as described previously (31), amplified in SF9
cells, and used for large-scale infection of Hi-5 cells under serum-free conditions.
The supernatant was concentrated and buffer exchanged into binding buffer (300
mM sodium citrate, 150 mM sodium chloride, 50 mM sodium phosphate, pH 8.0)
using a Centramate tangential-flow concentrator. E2 was purified by sequential
nickel affinity and size exclusion chromatography, and monodispersed fractions
of monomeric protein were collected and used for subsequent studies.
Generation, purification, and labeling of anti-HCV MAbs. MAbs were gener-
ated by five independent splenocyte-myeloma fusions as described previously
(43). Mice were immunized via an intraperitoneal route with sE2 produced from
either genotype 1a (H77) or 2a (J6) HCV strains after being complexed with the
RIBI Adjuvant System (Corixa Corp.) or complete Freund’s adjuvant (Sigma
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Chemical). Mice were boosted between two and five times with homologous
HCV sE2 protein complexed with either incomplete Freund’s adjuvant (Sigma),
the RIBI Adjuvant System (Corixa), or the Sigma Adjuvant system (Sigma),
depending on commercial availability, until adequate titers (1:2,500 by flow
cytometry) were achieved. The mice with the highest serum titers were boosted
intravenously with purified sE2 (50 mg) 3 days prior to fusion of splenocytes with
P3X63Ag8.53 myeloma cells (12). Hybridomas producing anti-HCV E2 antibod-
ies were identified after binding to Saccharomyces cerevisiae yeast cells expressing
sE2 on their surfaces by flow cytometry, subcloned by limiting dilution, and
isotyped by enzyme-linked immunosorbent assay (ELISA). For large-scale pro-
duction, MAbs were generated from ascites or adapted to growth in Hybridoma
Serum Free Medium (Gibco) and purified using protein A or G affinity chro-
matography (Pierce). In some experiments, MAbs were labeled with Alexa Fluor
647 (Molecular Probes) or NHS-FITC (fluorescein isothiocyanate) (Pierce)
MAb-labeling kits according to the manufacturer’s instructions.
Virus neutralization assays. Neutralization of HCV infection by viruses con-
taining genotype 1a structural proteins (H77/JFH1) was assessed by a focus-
forming unit (FFU) assay. Serial dilutions of HCV-specific MAb, control MAb
(WNV E16) (43), anti-human CD81 (clone JS81; BD Biosciences), or anti-
human SR-B1 (clone 396; Ab-Cam) were preincubated with 2.4  102 FFU of
virus for 1 h at 37°C. The virus-MAb mixtures were added to Huh-7.5 cells (1.2 
104 cells per well) in a 48-well tissue culture plate precoated with poly-L-lysine
(Sigma). After 72 h, the cells were fixed with methanol (0°C) and incubated
sequentially with a mouse anti-NS5A (APA-1; 40 ng/ml; a generous gift from
Apath, Inc.) (38) and secondary goat anti-mouse horseradish peroxidase (HRP)
diluted 1:3,000 (Sigma). FFU were visualized using the True Blue Peroxidase
Reagent (KPL) and quantitated using an S5 Biospot Macroanalyzer (Cellular
Technologies Ltd). The 50% effective concentration (EC50) values were deter-
mined using nonlinear regression analysis.
Neutralization of the genotype 2a (J6/JFH1/JC1) HCV was assessed by lucif-
erase assay. Serial dilutions of HCV-specific or control MAbs were preincubated
with the J6/JFH1/JC1 virus (102 FFU), which expresses luciferase, for 1 h at 37°C
and then added to Huh-7.5 cells (104 cells per well) in a 96-well black flat-bottom
polystyrene-treated microplate (Corning). After 48 h, the cells were lysed and
luciferase was detected using the Renilla Luciferase Assay System (Promega)
according to the manufacturer’s instructions. EC50 values were determined using
nonlinear regression analysis.
Neutralization of chimeric viruses with genotype 1a- to 6a-specific core-NS2
sequences was assessed by FFU assay as previously described (55). Briefly, 50 to
400 TCID50 of HCV was incubated for 1 h at 37°C with MAb H77.39 or an
isotype control and then incubated with cells for 3 h. After 48 h, the cells were
immunostained for NS5A as previously described (23). FFU counting was auto-
mated using an ImmunoSpot Series 5 UV Analyzer (22). The percent neutral-
ization was calculated by relating FFU counts to the mean of six replicates
incubated in the absence of antibody (virus only). Neutralization data were
analyzed as variable-slope dose-response curves using GraphPad Prism 4.0, and
EC50 values were interpolated by the software.
Pre- and post-virus attachment assays. To assess the abilities of MAbs to
inhibit H77/JFH1 virus at pre- and postattachment steps, FFU assays were
modified as follows. For the postattachment assay, prechilled cells were incu-
bated with 4.8  102 FFU of virus for 1 h at 4°C. Cells were washed thrice with
cold DMEM to remove unbound virus, MAbs (diluted to 50 g/ml in medium
and prewarmed at 37°C) were added, and the cells were shifted to 37°C. After
1 h, a 1:1 MEM-methylcellulose overlay with 4% FBS was added to prevent viral
spread. For the preattachment assay, 4.8  102 FFU of virus was preincubated
with 50 g/ml of MAb for 1 h at 37°C and then added to preseeded Huh-7.5 cells.
To assess the abilities of MAbs to inhibit J6/JFH1/JC1 at pre- and postattach-
ment steps, the luciferase assay was modified in the following manner. Forty-
eight-well tissue culture plates were precoated with poly-L-lysine (Sigma) and
seeded with 1.2  104 cells per well. For the postattachment assay, 4.8  102
FFU of virus was added to prechilled cells and “spinoculated” for 45 min at
400  g at 4°C, followed by a 15-min incubation at 4°C. The cells were washed,
and prewarmed MAbs and methylcellulose were added as described above. For
the preattachment assay, 4.8  102 FFU of virus was preincubated with 50 g/ml
of MAb for 1 h at 37°C and then added to preseeded Huh-7.5 cells. Cells from
both the pre- and postattachment assays were lysed after 48 h and transferred to a
96-well black-bottom plate, and luciferase was detected using the Renilla Luciferase
Assay System (Promega) according to the manufacturer’s instructions.
Cross-reactivity and mapping analysis of MAbs using yeast surface display.
To assess MAb cross-reactivity with other HCV genotypes, the ectodomain of
the E2 genes from genotype 1a (H77; amino acids 384 to 660), genotype 2a (J6;
amino acids 385 to 664), genotype 3a (UKN 3A13.6; amino acids 385 to 667),
genotype 4a (UKN 4.21.16; amino acids 392 to 663), genotype 5a (SA13 NIH;
amino acids 384 to 663), and genotype 6a (UKN 6; amino acids 385 to 668) was
amplified by PCR with BamHI and XhoI sites for cloning added at the 5 and 3
ends, respectively. The PCR products were cloned as downstream fusion proteins
to the Aga2 gene in the pYD1 vector (Invitrogen) for expression on the surface
of yeast. To determine the relative binding regions on the E2s of specific MAbs,
COOH-terminal truncation constructs, based on previous studies (41), were
generated for genotypes 1a and 2a corresponding to regions I (amino acids 384
to 520 in genotype 1a and 384 to 518 in genotype 2a) or I and II (amino acids 384
to 605 in genotype 1a and 384 to 603 in genotype 2a) and displayed on the surface
of yeast.
Expression constructs were transformed into Saccharomyces cerevisiae strain
EBY100 (17) using the S.c. EasyComp transformation Kit (Invitrogen). Individ-
ual yeast colonies were grown to logarithmic phase at 30°C in tryptophan-free
yeast selection medium containing 2% glucose. Protein expression was induced
by cultivating yeast for an additional 48 to 72 h in tryptophan-free medium
supplemented with 2% galactose at 20°C. Yeast cells were washed with PBS
containing 1 mg/ml bovine serum albumin (PBS-BSA) and incubated with 40 l
of MAb (neat supernatant or 20 g/ml purified and diluted in PBS) for 30 min
on ice. Yeasts were washed in PBS-BSA, incubated with goat anti-mouse IgG
secondary antibody conjugated to Alexa Fluor 647 (Molecular Probes) for 30
min on ice, washed, and analyzed on a FACSArray flow cytometer (Becton-
Dickinson) using FloJo software (Tree Star).
Random mutant libraries of E2 were generated from genotype 1a (strain H77)
and genotype 2a (strain J6) genes by error-prone PCR using a GeneMorph II
random-mutagenesis kit (Stratagene). The libraries were ligated into the pYD1
vector and transformed into XL2-Blue ultracompetent cells (Stratagene) with
5.7  105 and 5.5  105 transformants for genotypes 1a and 2a, respectively.
Screening of the libraries for loss-of-binding variants was performed as described
previously (43, 59). In brief, yeasts expressing E2 variants that lost specific
binding to individual MAbs were sorted using two-color flow cytometry. To
eliminate mutations that abolished surface expression of E2, yeasts were stained
sequentially with the Alexa Fluor 647-conjugated individual MAb, followed by a
FITC-conjugated oligoclonal pool of the cross-reactive MAbs (J6.1, J6.2, J6.16,
J6.39, J6.51, and J6.101 for the genotype 1a library and J6.2, J6.14, J6.15, J6.39,
J6.51, and J6.99 for the genotype 2a library) on ice for 30 min. Yeasts that stained
positively for the oligoclonal pool but negatively for the MAb of interest were
collected, cultivated, and iteratively sorted. In some cases, sorting was performed
using MACS LS magnetic columns (Miltenyi Biotech). In brief, 107 yeast cells
were pelleted and resuspended in MACS buffer (PBS plus 0.5% BSA plus 2 mM
EDTA) containing a 1:50 dilution of a FITC-labeled MAb of interest for 30 min,
washed, and then incubated with 10 l of anti-FITC microbeads (Miltenyi Bio-
tech) on ice for 15 min. The yeasts were washed and passed over a MACS LS
column, and the flowthrough was collected. After four or five rounds, the yeasts
were plated, and individual colonies were tested for binding to individual MAbs
by flow cytometry. For clones that lost binding to the desired MAb of interest,
the plasmid was recovered using a Zymoprep yeast minipreop kit (Zymo Re-
search), transformed into XL1-Blue competent Escherichia coli, purified using a
QIAprep spin miniprep kit (Qiagen), and sequenced. In cases where more than
one mutation was detected, site-specific mutagenesis using the Quick Change II
Mutagenesis kit (Stratagene) was used to generate individual mutations within
the E2 protein to define the mutant of interest.
Inhibition of CD81 and SR-B1 binding. To assess the abilities of neutralizing
MAbs to inhibit binding of sE2 to CD81 and SR-B1, 50 g/ml of purified MAb
was preincubated with 20 g/ml H77 E2 or J6 sE2 for 30 min at 37°C. CHO cells
expressing HCV receptors were detached with PBS supplemented with 4 mM
EDTA and 10% FBS and washed three times in medium. Cells (105) were
pelleted in a V-bottom plate, resuspended with MAb-protein mixture, and in-
cubated on ice for 30 min. The cells were washed and then incubated with a pool
of Alexa Fluor 647-labeled anti-E2 MAbs (J6.1, J6.2, J6.39, J6.51, H77.30, and
H77.34 for the detection of H77 E2 and J6.2, J6.39, J6.51, J6.60, and J6.101 for
the detection of J6 E2) for 20 min on ice. The cells were washed twice, and sE2
binding was analyzed on a FACSArray flow cytometer (Becton-Dickinson) using
FloJo software (Tree Star).
Statistical analysis. All data were analyzed using Graphpad Prism software
(version 4.0). For neutralization assays and receptor-binding assays, an unpaired
t test was used to determine statistical significance.
RESULTS
MAb generation. Previous studies have demonstrated that
HCV-specific monoclonal and polyclonal antibodies, particu-
larly those that recognize the E2 protein, can control HCV
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FIG. 1. Identification of neutralizing anti-E2 antibodies against HCV. (A) Examples of MAb neutralization as judged by a reduction in the
number of FFU, using the Biospot Macroanalyzer. Spot counts are shown below each well, and well numbers are shown above. Wells 1 through
8 represent decreasing (3-fold) concentrations of the neutralizing MAb H77.39 (starting concentration, 50 g/ml). Well 9 shows infection in the
absence of MAb, and well 10 is an uninfected well. The data are representative of three independent experiments performed in duplicate. (B) MAb
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infection in vitro and in vivo (10, 15, 33, 37, 47, 62). However,
only a few of these antibodies have been characterized for the
ability to inhibit at different stages of HCV infection or
mapped to epitopes at the amino acid level. To better define
the structural basis of antibody neutralization of HCV, we
generated a new panel of anti-HCV MAbs by immunizing
BALB/c mice with soluble, recombinant E2 protein that was
expressed in insect cells and derived from either genotype 1a
(strain H77; amino acids 384 to 664) or genotype 2a (strain J6;
amino acids 385 to 664) viruses. After five independent spleno-
cyte-myeloma cell fusions, we subcloned 37 MAbs from geno-
type 1a-immunized mice and 41 MAbs from genotype 2a-
supernatant was mixed with the H77-JFH1 chimeric HCV for 1 h at 37°C, and Huh-7.5 cells were infected. Three days later, neutralization was
determined by FFU assay. MAb supernatants that decreased the number of FFU to 40% or less (below the solid black line) of the negative-control
MAb (anti-WNV E122), as well as additional selected MAbs, were purified for testing in full dose-response analysis. The data are pooled from
three independent experiments performed in duplicate. (C) Serial dilutions of genotype 1a-specific purified MAbs were mixed with H77-JFH1
chimeric virus, and neutralization was assessed. Efficient neutralization was observed for five (H77.16, H77.28, H77.31, H77.39, and H77.56)
genotype 1a-specific MAbs, but not for the negative-control MAb (data not shown). EC50 values were calculated after nonlinear regression analysis.
The data are pooled from at least three independent experiments performed in duplicate. (D) Increasing concentrations of purified genotype
2a-specific MAbs (J6.36 and J6.103) were mixed with J6-JFH1-JC1-luciferase-expressing virus. At 48 h, neutralization was assessed in Huh-7.5 cells
by monitoring luciferase expression. EC50 values were calculated after nonlinear regression analysis. The data are pooled from at least three
independent experiments performed in duplicate. All error bars represent the standard errors of the mean.
FIG. 2. Identification of MAbs that bind heterologous HCV genotypes using yeast display of E2 protein. The E2 ectodomain gene from six strains
corresponding to HCV genotypes 1 to 6 was cloned into the PYD1 vector and expressed on the surface of yeast (see Materials and Methods). Yeasts
expressing HCV E2 were incubated with MAb supernatants, and binding was assessed by flow cytometry. Representative histograms from all neutralizing
MAbs (H77.16, H77.28, H77.31, H77.39, H77.56, J6.27, J6.36, and J6.103; solid black histograms) and negative-control MAb (WNV E16; unfilled gray
histograms) are depicted. The data are representative of at least three independent experiments.
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immunized mice, all with reactivity against the E2 structural
glycoprotein of HCV (see Table S1 in the supplemental ma-
terial).
Neutralizing activities of anti-E2 MAbs. To study the inhib-
itory capacity of genotype 1a MAbs in cell culture, we utilized
an H77-JFH1 chimeric infectious virus that contains genotype
1a core-NS2 sequence in the JFH1 background, with a com-
pensatory Q221L mutation in NS3 (pHJ3-5) (40, 67). For high-
throughput screening, we adapted an FFU assay with Huh-7.5
cells so that infectious foci were scored objectively on an en-
zyme-linked immunospot (ELISPOT) reader, and the reduc-
tion in the number of FFU was assessed after preincubation of
virus with individual MAbs (Fig. 1A). We performed a single-
endpoint focus reduction neutralization test (FRNT) using
neat antibody supernatant (10 g/ml) and identified 9 MAbs
that inhibited infection by 40% or greater (Fig. 1B). The can-
didate neutralizing MAbs identified above and other selected
antibodies were purified by immunoaffinity chromatography
and tested for inhibitory activity with a more complete dose-
response curve (Fig. 1C). We demonstrated that five of these
MAbs (H77.16, H77.28, H77.31, H77.39, and H77.56) had re-
producible neutralizing activity and determined the concentra-
tion of MAb at which 50% of foci were inhibited (the EC50
value) (Fig. 1C). Of these MAbs, H77.16 and H77.39 showed
the greatest inhibitory activity, with EC50 values of 3.4 g/ml
and 1.1 g/ml, respectively.
To evaluate the neutralizing activities of MAbs generated
against E2 derived from the genotype 2a HCV strain, we uti-
lized a genotype 2a J6/JFH1/JC1 infectious chimera of HCV
that contains a Renilla luciferase reporter gene inserted imme-
diately upstream of an NS2A cleavage site (58). All 41 MAbs
that bound the genotype 2a E2 protein were purified and
assessed for inhibitory activity over a broad range of concen-
trations to determine the concentration of antibody that re-
duced luciferase expression by 50% (EC50 value) (data not
shown). We identified two antibodies, J6.36 and J6.103, that
efficiently neutralized infection, (Fig. 1D), with J6.36 having an
EC50 value below 2 g/ml. Notably, no significant difference in
the inhibitory potency of a given neutralizing MAb was ob-
served when the luciferase and FRNT assays were directly
compared (data not shown).
Cross-reactivity of anti-E2 MAbs. HCV is comprised of six
epidemiologically important genotypes with 70% nucleotide
identity (4). A better understanding of the specific epitopes
that are conserved and recognized by inhibitory antibodies may
facilitate the design of future vaccines. To begin to address
this, we assessed how genotype variation affected MAb reac-
tivity using recombinant E2 proteins displayed on yeast (1a,
H77; 2a, J6; 3a, UKN 3a; 4a, UKN 4a; 5a, SA13; and 6a, UKN
6) and neutralization capacity with chimeric HCV strains (1a,
H77; 2a, J6; 3a, S52; 4a, ED43; 5a, SA13; and 6a, HK6a)
containing the nonstructural proteins (NS3 to NS5B) of the
genotype 2a JFH1 strain and structural proteins, p7, and NS2
from strains representative of HCV genotypes 1 to 6.
(i) Binding to different HCV genotypes. The ectodomain of
E2 from individual strains corresponding to HCV genotypes 1
to 6 was expressed on the surface of yeast, incubated with
MAbs, and analyzed for binding by flow cytometry. Three of
the eight neutralizing MAbs were broadly cross-reactive and
recognized all five (H77.16 and H77.39) or four of the five




1a(H77) 2a(J6) 3a(UKN 3) 4a(UKN4) 5a(SA13) 6a(UKN6)
J6.1      
J6.2      
J6.6      
J6.7      
J6.8      
J6.9      
J6.12      
J6.13      
J6.14      
J6.15      
J6.16      
J6.21      
J6.23      
J6.25      
J6.27      
J6.30      
J6.33      
J6.34      
J6.36      
J6.39      
J6.40      
J6.42      
J6.48      
J6.49      
J6.51      
J6.56      
J6.58    /  
J6.60      
J6.62      
J6.67      
J6.68      
J6.75      
J6.76      
J6.81      
J6.85      
J6.86      
J6.91      
J6.98      
J6.99      
J6.101      
J6.103      
H77.1      
H77.7      
H77.8      
H77.9      
H77.11      
H77.12      
H77.13      
H77.14      
H77.16      
H77.17      
H77.18      
H77.19      
H77.22      
H77.23      
H77.27      
H77.28      
H77.29      
H77.30      
H77.31      
H77.32      
H77.33      
H77.34      
H77.35      
H77.36      
H77.37      
H77.38      
H77.39      
H77.42      
H77.43      
H77.44      
H77.45      
H77.46      
H77.47      
H77.50      
H77.53      
H77.55      
H77.56      
a , strong binding (40 to 100%) to yeast expressing E2; , weak binding
(15 to 40%) to yeast expressing E2; , no appreciable binding detected. The data
are a summary of 3 to 5 independent experiments.
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(H77.56) heterologous genotypes (Fig. 2 and Table 1). Three
of the neutralizing MAbs (H77.31, J6.36, and J6.103) bound to
yeast expressing only the homologous E2.
(ii) Cross-neutralizing potential of MAbs. As the MAb bind-
ing capacity to recombinant viral structural proteins does not
always directly correlate with the neutralizing potential (8), we
evaluated the inhibitory activities of several of the cross-reac-
tive MAbs against HCV of other genotypes. Initially, single-
endpoint focus reduction assays were performed with high
concentrations (50 g/ml) of purified MAbs generated against
genotype 1a or genotype 2a that cross-reacted with genotype
2a or genotype 1a E2, respectively (Fig. 3A and B). Of the
cross-reactive MAbs generated against genotype 1a E2, only
H77.39 neutralized the genotype 2a virus. Of the cross-reactive
MAbs generated against genotype 2a E2, only J6.27 inhibited
genotype 1a HCV infection (Fig. 3B and C). This was surpris-
ing, because J6.27 lacked neutralizing activity against the ge-
notype 2a strain against which it was generated (Fig. 3C); this
pattern of enhanced neutralizing activity of cross-reactive an-
tibodies against the heterologous virus has also been observed
with MAbs against distantly related flaviviruses (2, 44). H77.39
inhibited the genotype 2a virus with an EC50 of 5 g/ml (Fig.
3D), which was comparable to that observed with the genotype
1a virus (Fig. 1C). We subsequently tested whether H77.39
neutralized infection of a panel of chimeric viruses that ex-
pressed structural proteins from the remaining heterologous
HCV genotypes. H77.39 dose-dependently inhibited HCV in-
fection of genotypes 3a, 4a, and 5a but showed reduced activity
against a virus containing structural proteins of genotype 6a
(Fig. 3E).
Mechanism of MAb neutralization. Antibody neutralization
may involve different stages of viral infection, including attach-
ment, internalization, and fusion (51). To begin to understand
how our inhibitory MAbs blocked infection, we performed pre-
and postattachment neutralization assays and studies of bind-
ing to the CD81 and SR-B1 receptors.
(i) Pre- and postattachment assays. To identify the stage of
infection at which MAbs neutralize infection, we adapted a
pre- and postattachment inhibition assay originally developed
for flaviviruses (42, 60, 66). Purified anti-E2 MAb was incu-
bated with virus before or after attachment at 4°C to Huh-7.5
cells, and infection was measured by a single-endpoint focus
reduction assay. Of the nine neutralizing MAbs tested, three
(H77.16, H77.39, and J6.36) significantly reduced infection
compared to the negative-control MAb (WNV E16) when
added after viral absorption to a cell monolayer, suggesting
blockade of a postattachment step (Fig. 4A to D). Interest-
ingly, both anti-CD81 and anti-SR-B1 MAbs also inhibited
infection after viral adsorption, confirming previous results in
Huh-7.5 cells which suggested that HCV binds to CD81 and
SR-B1 after initial attachment (6, 25). Inhibition of infection at
a postattachment step by H77.39 was confirmed by performing
more complete dose-response curve analyses (Fig. 4E).
(ii) MAb inhibition of sE2 binding to receptors. Given that
anti-CD81, anti-SR-B1, and several anti-E2 MAbs all blocked
after HCV attached to Huh-7.5 cells, it was difficult to discern
FIG. 3. MAb neutralization of heterologous HCV genotypes. (A and B) MAbs that were generated against genotype 1a (A) or genotype 2a
(B) E2 proteins were tested for the ability to neutralize infection by virus from the heterologous genotype. Purified J6 or H77 MAbs (50 g/ml)
were preincubated at 37°C with H77-JFH1 (genotype 1a) or J6-JFH1-JC1 (genotype 2a) virus, respectively, and neutralization was assessed as
described in the legend to Fig. 1. (C to E) EC50 analysis was performed with J6.27 MAb and H77-JFH1 virus (f) or J6-JFH1-JC1 virus (E) (C),
H77.39 MAb and J6-JFH1-JC1 virus (E) (D), or H77.39 MAb and H77C/JFH1 (f), S52/JFH1 (), ED43/JFH1 (}), SA13/JFH1 (F), and
HK6a/JFH1 () chimeric viruses (E). The graphs represent pooled data from at least three independent experiments performed in duplicate (A
to D) or two independent experiments performed in triplicate (E), and the error bars represent the standard errors of the mean.
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whether some antibodies blocked binding to individual HCV
receptors. To address this, we developed an assay for sE2
binding to CHO cells that ectopically expressed human CD81
or SR-B1. CHO cells were transduced with a lentiviral vector
encoding CD81 or SR-B1 fused to GFP. Surface staining of
intact cells with anti-CD81 and anti-SR-B1 MAbs confirmed
high-level receptor expression (Fig. 5A), as did analysis of cells
for GFP fluorescence (data not shown). Binding of genotype
1a (Fig. 5B) and genotype 2a (Fig. 5C) sE2 to CD81- and
SR-B1-expressing CHO cells (solid histograms), but not con-
trol CHO cells (outlined histograms), was confirmed by flow
cytometry. To determine whether sE2-CD81/SR-B1 receptor
interactions could be disrupted by anti-E2 MAbs, neutralizing
or control (anti-WNV E16) MAbs were preincubated with sE2
and added to wells containing CHO cells expressing CD81 or
SR-B1, and loss of binding was assessed by flow cytometry (Fig.
5D). The neutralizing MAb H77.39 significantly blocked
(70%; P 	 0.01) sE2 binding to both CD81 and SR-B1. In
comparison, H77.31 also reduced binding of sE2 to both re-
ceptors, although inhibition of SR-B1 binding was more mod-
est (40%; P 
 0.04) than that seen with CD81 (80%; P 

0.003). Conversely, J6.36 efficiently inhibited sE2–SR-B1 bind-
ing (80%; P 
 0.0002) yet only modestly (50%; P 	 0.05)
diminished sE2-CD81 binding. H77.16 and J6.103 blocked sE2
binding to only a single receptor, with both efficiently reducing
(75%; P 
 0.0005) binding to SR-B1 (Fig. 5D). Three neu-
tralizing MAbs, H77.28, H77.56, and J6.27, did not significantly
inhibit sE2 attachment to either CD81 or SR-B1, suggesting
that they may block an alternate attachment or entry step
(Fig. 5E).
FIG. 4. Pre- or postattachment neutralization. (A to D) To determine whether MAbs neutralize HCV infection at a postattachment step,
Huh-7.5 cells were prechilled at 4°C, and 480 FFU of genotype 1a (H77-JFH1) (A) or genotype 2a (J6-JFH1-JC1) (B) virus was added to each
well for 1 h at 4°C. After three washes with 4°C DMEM, saturating concentrations of MAbs (50 g/ml) were added for 1 h at 37°C, and the
neutralization assay was completed. In comparison, a standard preincubation neutralization test was performed at 37°C, in which genotype 1a virus
(C) or genotype 2a virus (D) and MAb were preincubated at 37°C prior to addition to cells. The data shown are the averages of three independent
experiments, with the error bars representing standard errors of the mean. Statistically significant differences in neutralization are compared to
infection in the presence of a negative-control MAb (WNV E16): *, P 	 0.05; **, P 	 0.01; and ***, P 	 0.001. (E) To confirm the ability of
H77.39 to neutralize infection at both pre- and postattachment steps, a dose-response curve was performed under both pre- and postattachment
conditions, as described above, using H77/JFH1 virus. The graphs represent pooled data from at least three independent experiments performed
in duplicate, and the error bars represent the standard errors of the mean.
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Epitope localization of MAbs. To correlate the functions of
the anti-E2 MAbs with the structure of the HCV E2 protein,
we localized their epitopes using a previously validated yeast
surface display mapping assay (43, 44, 61). Initially, COOH-
terminal truncated versions of E2, based on those described
previously (41), were displayed on the surface of yeast, and
MAbs were tested for immunoreactivity by flow cytometry
(Fig. 6) (see Table S1 in the supplemental material). Neutral-
izing MAbs showed different requirements for binding. H77.16,
H77.39, J6.36, and J6.103 bound to a region bracketed by
amino acids 384 to 520 of genotype 1a and 384 to 518 of
genotype 2a E2 (designated “region I”), whereas H77.28,
H77.31, and J6.27 required amino acids 521 to 605 of genotype
1a or 519 to 603 of genotype 2a E2 (designated “region II”) for
binding. In contrast, MAb H77.56 required the full E2 ectodo-
main (amino acids 1 to 664), suggesting that it interacts with
amino acids 606 to 664 alone or requires a conformation of E2
that this region stabilizes. MAbs that neutralized efficiently at
a postattachment step, H77.16, H77.39, and J6.36, all bound to
region I of E2.
To localize MAb epitopes more clearly, we used error-prone
PCR mutagenesis and yeast surface display to create a library
of H77 and J6 E2 variants to define individual amino acid
binding residues of neutralizing and nonneutralizing MAbs.
Yeasts that lost expression of individual MAb epitopes were
sorted by flow cytometry, and plasmids were recovered, se-
quenced, and tested for reactivity against a select panel of
MAbs (Fig. 7 and Tables 2 and 3).
H77.39, the most potent and highly cross-neutralizing MAb,
showed markedly reduced binding when residues N415 and
N417 of E2 were changed (Fig. 7A and Table 2). Two neutral-
izing MAbs (J6.36 and J6.103) showed significant loss of bind-
ing when a pair of mutations was introduced. J6.36 and J6.103
lost binding with changes in HVR1 and a more distal region of
E2; mutation of residues G406 and F403 or a combined mu-
tation at residues G397 and R572 abrogated MAb binding.
FIG. 5. Inhibition of sE2 binding to CD81 and SR-B1 by neutralizing MAbs. (A) Verification of ectopic CD81 and SR-B1 receptor expression
on CHO cells. CHO-CD81 or CHO–SR-B1 cells were incubated with either mouse anti-hCD81 or rabbit-anti-hSR-B1 (black histograms) or an
irrelevant MAb (unfilled gray histograms) for 30 min on ice. The cells were washed, incubated with the appropriate secondary antibodies, and
processed by flow cytometry. (B and C) Binding of genotype 1a (H77) E2 (B) or genotype 2a (J6) E2 (C) to CHO-CD81 and CHO–SR-B1, but
not wild-type (WT) CHO cells. CHO-CD81 or CHO–SR-B1 (solid black histograms) or WT CHO (unfilled gray histograms) cells were incubated
with sE2, and binding was assayed by flow cytometry. The data are representative of at least three independent experiments. (D) Assessment of
inhibition of sE2 binding to CHO-CD81 or CHO–SR-B1 cells by neutralizing MAbs. sE2 was preincubated with neutralizing MAbs and added to
CHO cells, and binding was detected by flow cytometry. Examples of MAbs that inhibit sE2 binding to CD81 preferentially (H77.31), to both CD81
and SR-B1 (H77.39), or only to SR-B1 (J6.103), as well as a negative-control MAb (WNV E16), are shown. The histograms are representative of
three individual experiments. The solid black histograms represent sE2 binding in the presence of MAb, the red histograms represent sE2 binding
in the absence of MAb, and the shaded gray histograms represent sE2 binding to CHO WT cells. (E) Graphical representation of sE2 binding to
CHO-CD81 and CHO–SR-B1 cells in the presence of neutralizing MAbs. The values were determined by dividing the fluorescence quotient (mean
fluorescence intensity  percent positive cells) for E2 binding in the presence of a neutralizing MAb by the fluorescence quotient of sE2 binding
to either CHO-CD81 or CHO–SR-B1 cells alone. The asterisks represent statistically significant differences in sE2 binding compared to the
negative-control MAb, WNV E16: *, P 	 0.05; **, P 	 0.01; and ***, P 	 0.001. The error bars represent the standard errors of the mean. The
data are pooled from three independent experiments.
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Single mutations of G397 and R572, however, did not affect
binding (Fig. 7B and Table 3). Similarly, H77.16 showed
weakly reduced binding when a serine was introduced at resi-
due G406 (Fig. 7A) but complete loss of binding when residue
G530 was altered in combination with G406S. However, com-
plete loss of H77.16 binding also was observed when residue
G406 was mutated to an aspartic acid residue.
The neutralizing MAbs that were quantitatively weaker in
our neutralization assays, H77.31 and J6.27, showed decreased
binding when residues in the putative CD81 binding region
(amino acids 523 to 535) (48) were changed. H77.31 binding to
E2 on yeast was lost when residues W529, G530, and D533
were mutated, whereas J6.27 binding was abolished when
amino acids A524 and W529 were altered. The remaining two
weakly neutralizing MAbs (H77.28 and H77.56) showed re-
duced binding with changes at residues R543 and C552, re-
spectively (Fig. 7A and Tables 2 and 3).
Some nonneutralizing MAbs also were mapped. Several
nonneutralizing MAbs (H77.27, H77.36, J6.2, J6.6, J6.15, J6.39,
and J6.85) shared residues that impacted binding of H77.31 or
J6.27 (Tables 2 and 3), and a few (J6.2, J6.6, J6.40, and J6.101)
had total or partial loss of binding to residue G406, which was
identified as an important recognition residue for the neutralizing
MAbs H77.16, J6.36, and J6.103. In addition to G406, J6.2, J6.40,
and J6.101 recognition was also affected by mutation of residue
H621, thus defining another discontinuous epitope, albeit one
that is not apparently involved in neutralization (Fig. 7 and Tables
2 and 3). Additional residues that uniquely affected binding by
nonneutralizing MAbs included G470 (H77.14 and H77.23), S440
(J6.60), Y443 (J6.60), and H621 (J6.30).
DISCUSSION
In this study, we generated a novel panel of 78 MAbs against
the E2 proteins of HCV genotypes 1a and 2a, analyzed them
functionally for inhibition of HCV infection, and localized
epitopes using yeast surface display of truncated and substi-
tuted forms of the E2 protein. We defined MAbs that mapped
to distinct regions of E2, neutralized infection at different
stages, and differentially affected CD81 and SR-B1 engagement.
Our mapping data also suggest a tertiary interaction between
HVR1 and the COOH-terminal membrane-proximal regions of
E2, which provides new insight into the quaternary structural
aspects of neutralization by functionally relevant antibodies.
Prior mapping studies of anti-E2 MAbs have utilized pep-
tide binding (9, 18), phage display (65), alanine-scanning mu-
tagenesis of recombinant E1-E2 (33, 37, 49, 62) or E2 (34), or
generation of neutralization escape mutants (19) to localize
antibody binding sites. In comparison, we used a forward ge-
netic mutational approach coupled with yeast surface display
to identify mutants in the context of the entire ectodomain of
E2 protein in an unbiased manner. Three of our eight neutral-
izing MAbs showed loss-of-binding phenotypes with paired
amino acid mutations greater than 100 amino acids apart in the
linear sequence, suggesting that discontinuous regions of E2
come together to create functionally important antibody epitopes.
H77.16 showed a loss-of-binding phenotype when mutations in
HVR1 (e.g., G406S) and the more COOH-terminal residue
(G530A) were paired, suggesting that H77.16 binds a confor-
mational epitope. Although complete loss of binding could be
achieved with a single less conserved mutation (G406D), the
more conserved G406S change required a second mutation at
a discontinuous site (G530) for loss of binding. This finding,
which suggests that HVR1 interacts with more COOH-termi-
nal residues, is consistent with MAb competition studies with
recombinant proteins that suggested that amino acids 396 to
424, 436 to 447, and 523 to 540 comprise an antigenic region
(designated “antigenic region 3”) within E2 (37) and with
sequencing results of MAb AP33 escape variants, which identified
FIG. 6. Mapping of anti-E2 antibodies using COOH-terminal trun-
cation mutants. (A) Scheme of E2 truncations used for mapping.
cDNA containing region I (aa 384 to 520 and aa 384 to 518 in E2 of
genotypes 1a and 2a, respectively) or I and II (aa 384 to 605 and 384
to 603 in E2 of genotypes 1a and 2a, respectively) and the full-length
ectodomain (aa 384 to 664) were displayed on the surface of yeast.
(B) MAb supernatants were incubated with yeast and assessed for
binding by flow cytometry. Neutralizing MAbs binding to regions I
(H77.16, H77.39, J6.36, and J6.103) and II (H77.28, H77.31, and J6.27)
and the full-length E2 ectodomain (H77.56) are shown. The solid black
histograms depict binding of HCV-specific MAbs, and the gray unfilled
histograms represent binding of a negative-control MAb (WNV E16).
The histograms are representative of three independent experiments.
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noncontiguous amino acid residues (N415 and E655) as factors in
the loss-of-neutralization phenotype (19). Additionally, these
data support the recently described model of HCV E2 based on
the three-domain structure of class II E proteins in Flaviviridae
and Togaviridae, which predicts that HVR1 proximally apposes
the proposed HCV domain I (D1) (36) (Fig. 8B).
Two other neutralizing MAbs, H77.31 and J6.27, also rec-
ognized residues within the third segment of antigenic region 3
(A524, W529, G530, and D533) but did not show a loss-of-
binding phenotype when amino acids within segment 1 (396 to
424) were changed. These two MAbs less potently neutralized
infection and were less cross-reactive. In comparison, human
anti-HCV MAbs (A8, 1:7, and CBH5) that share epitopes in
this region (26, 33) have been characterized as inhibitory and
cross-reactive (Table 4). Although further analysis is required,
the differences in function of the mouse and human MAbs
could be related to affinity or possibly to the fact that the
human MAbs bind additional sites and do not exclusively rec-
ognize the linear epitope centered at residues G523 to D535,
as was suggested in previous studies (1, 26).
The neutralizing MAbs J6.36 and J6.103 also mapped to a
discontinuous epitope, requiring residues within HVR1 (G397,
FIG. 7. Epitope localization of anti-HCV MAbs. Binding of neutralizing MAbs to yeast expressing E2 protein variants. (A) Flow cytometry
histograms of wild-type and loss-of-binding genotype 1a E2 variants (G406D, G406S, N410Y, I411N, N415Y, N417T, W529R, G530A, D533N,
R543G, C552S, and G406S plus G530A). Representative histograms are shown for the MAbs H77.14, H77.16, H77.28, H77.31, H77.39, H77.56,
and WNV E16 (negative control) with WT H77 E2 and each of the variants. The data shown are representative of three independent experiments.
The red arrows indicate 80% loss of binding of a specific MAb for a given variant. (B) Flow cytometry histograms of wild-type and
loss-of-function genotype 2a E2 variants (G397E, F403L, G406C, A524V, W529C, R572S, H621L, and G397E plus R572S) with individual
neutralizing MAbs. Representative histograms are shown for the MAbs J6.27, J6.36, J6.101, J6.103, and WNV E16 (negative control) with the
wild-type E2 and each of the variants. The data shown are representative of three independent experiments. The arrows indicate 80% loss of
binding of a specific MAb for a given variant.
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F403, and G406) and the more COOH-terminal residue R572.
Although neutralizing MAbs (9/27 [18, 30] and AP213 [65]) have
been mapped to HVR1, to our knowledge, MAbs that bind res-
idues at or near R572 have not been identified. MAb 9/27 does
not block binding of sE2 to CD81 (18, 30), although it did inhibit
HCV VLP interaction with CD81 (45), suggesting that it also may
recognize a conformational or possibly oligomeric epitope.
The MAb in our study with the greatest inhibitory activity,
H77.39, localized to 2 amino acids, N415 and N417, that are
highly conserved among all HCV genotypes (48, 65). N415 and
N417 were defined previously as possible binding residues for
MAbs AP33 and 3/11 (11, 19, 62) (Table 4). Residue N417
comprises part of a highly conserved N-linked glycosylation
site (20, 21) that is implicated in obscuring antibody-mediated
neutralization (27). H77.39, as well as AP33 and 3/11, is thus
unique in mapping to an N-linked glycan that is paradoxically
hypothesized to impair antibody recognition.
To relate binding epitopes to function, MAbs were tested for
the ability to inhibit sE2 engagement with the HCV cognate
receptors CD81 and SR-B1. The MAbs J6.36, J6.103, and
H77.16, which recognized residues within HVR1, as well as the
more COOH-terminal region, blocked sE2–SR-B1 binding.
These results are consistent with data suggesting HVR1 par-
ticipates in SR-B1 binding (3, 5, 56) and that the HVR1-
specific MAb 9/27 inhibits sE2–SR-B1 interactions (5, 56).
Although J6.36 did not map to any of the predicted CD81
binding residues (48), it partially inhibited sE2 binding to
CD81. J6.36 could map to additional amino acid residues
(within the CD81 binding site) not identified in our study, or
steric hindrance could mediate this partial inhibition. In the
TABLE 2. Summary of MAb binding to genotype 1 mutants expressed on the surface of yeast
MAb
Bindinga
G406D G406S N410Y I411N N415Y T416I N417T G470A W529R G530A G530D D533N R543G C552S G406S G530A
G406D 
G530D
H77.14 100 100 100 100 67 100 58 <1 100 91 100 100 66 100 100 100
H77.16 <1 58 <1 <1 76 97 100 100 100 97 100 100 100 100 <1 <1
H77.23 100 100 100 100 75 100 61 <1 100 100 100 100 89 100 100 100
H77.27 77 91 100 97 64 100 80 81 <1 <1 11 27 84 100 <1 <1
H77.28 96 100 100 74 38 96 57 74 100 61 100 76 <1 >500 100 100
H77.31 77 100 100 100 96 100 65 100 <1 <1 24 <1 100 100 <1 <1
H77.36 97 88 100 92 100 100 98 100 1.2 26 <1 80 100 100 21 <1
H77.39 100 100 100 100 <1 81 <1 61 100 100 100 100 50 100 100 100
H77.56 100 100 100 100 100 100 100 100 100 100 100 92 100 9.5 100 100
a The values shown were obtained by dividing the total fluorescence product (percent positive population  mean fluorescence intensity) of a mutant for a given MAb
by the total fluorescence product of the wild-type E2 for a given MAb. This value was then divided by the total fluorescence product of a mutant for an oligoclonal
MAb pool and by the total fluorescence product of WT E2 for the same oligoclonal pool (to control for E2 binding) and multiplied by 100. The values in boldface
indicate complete loss of binding, with reductions in MAb binding greater than or equal to 80% for a given mutation. The underlined values indicate a partial reduction
in binding, between 50 and 79%. The italicized, boldface, and underlined value shows enhancement of binding greater than 500%. The results are the averages of three
independent experiments for each mutant and each antibody.
TABLE 3. Summary of MAb binding to genotype 2a mutants expressed on yeast
MAb
Bindinga
G397E F403L G406C S440P Y443C A524V W529C E531V R572S H617L G397E R572S
J6.1 71 97 100 100 83 83 100 88 100 100 61
J6.2 71 100 16 100 93 73 20 68 42 6 56
J6.6 64 100 26 41 100 6 4 69 100 100 100
J6.15 100 100 100 75 85 66 13 34 100 100 79
J6.16 100 100 100 76 100 80 100 86 100 100 100
J6.27 74 67 100 90 95 <1 <1 77 83 100 80
J6.30 85 100 100 100 75 58 88 82 100 3 100
J6.36 100 <1 <1 60 95 80 100 100 100 100 <1
J6.39 94 91 100 100 83 100 3 63 100 100 81
J6.40 98 100 32 32 100 75 63 65 40 15 80
J6.60 51 58 100 <1 <1 65 90 81 70 73 77
J6.75 100 100 100 100 100 100 100 100 100 100 100
J6.85 100 100 100 100 91 72 10 27 100 100 80
J6.101 83 100 43 100 100 100 57 91 82 3 50
J6.103 100 2 <1 26 100 100 100 100 100 100 <1
a The values shown were obtained by dividing the total fluorescence product (percent positive population  mean fluorescence intensity) of a mutant for a given MAb
by the total fluorescence product of the wild-type E2 for a given MAb. This value was then divided by the total fluorescence product of a mutant for an oligoclonal
pool of MAbs and by the total fluorescence product of WT E2 for the oligoclonal pool (to control for E2 binding) and multiplied by 100. The values in boldface indicate
complete loss of binding, with reductions in MAb binding greater than or equal to 80% for a given mutation. The underlined values show partial loss of binding, with
a reduction between 50 and 79%. The results are the averages of three independent experiments for each mutant and each antibody. Polyprotein amino acid numbering
was determined by alignment with the H77 strain using the Sequence Location tool on the Los Alamos HCV database (http://hcv.lanl.gov/cgi-bin/LOCATE/locate.cgi).
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recently modeled E2 structure (36), the J6.36-interacting res-
idues lie in proximity to the HCV D1, which is predicted to
contain key CD81 binding residues (36, 48) (Fig. 8B). Con-
versely, H77.31, which potently inhibited CD81 binding and
maps to residues (W529 and G530) involved in CD81 binding
(48), partially inhibited SR-B1 engagement despite a lack of
contact residues in HVR1. The inability of J6.103 to inhibit
binding to CD81 despite localizing to the same residues as
J6.36 could be explained by overlapping but not identical MAb
footprints or perhaps differences in affinities of interaction.
Only one MAb, H77.39, potently inhibited sE2 binding to
both CD81 and SR-B1. Interestingly, H77.39 did not map to
residues within known SR-B1 or CD81 binding regions, sug-
gesting that it may recognize a site that, once occupied, can
sterically prevent receptor engagement. This concept is sup-
ported by studies showing that N415 and N417 can obscure the
CD81 and SR-B1 binding sites (11, 27). Finally, the E2 model
recently proposed by Krey et al. predicts that residues N415 to
N417 lie at the junction of HVR1 and D1 (Fig. 8B), in prox-
imity to both HVR1 and the CD81 binding residues located
within the C and D loops of D1 (36, 48).
Pre- and postattachment neutralization studies provided ad-
ditional insight into the relative potencies of MAbs. Studies
with distantly related flaviviruses have shown that MAbs inhib-
iting at a postattachment step tend to have greater inhibitory
activity in vitro and in vivo because they require reduced virion
FIG. 8. Localization of MAb binding residues on E2. (A) Alignment of E2 sequences from HCV genotypes 1 to 6 with superimposed mapping
of MAb binding residues. The sequences of E2 from strains representative of the different genotypes (genotype 1a, H77; genotype 2a, J6; genotype
3a, UKN 3; genotype 4a, UKN 4a; genotype 5a, SA513; genotype 6a, UKN 6) used in the yeast-mapping studies (Fig. 2) were aligned. Colored
boxes and symbols were used to highlight neutralizing MAb binding residues as follows: red boxes, J6.36 and J6.103; purple boxes, H77.39; blue
underscoring, H77.16; green boxes, J6.27; pink circles, H77.31; orange box, H77.28; yellow box, H77.56. (B) Putative model of the structure of the
E2 protein with MAb binding regions highlighted. A scheme depicting a possible E2 structure was adapted from Krey et al. (36) to highlight regions
involved in MAb recognition. N-linked glycosylation residues are labeled in green, and amino acids are numbered in black at intervals; -sheets
in D1 are labeled as previously described (36). MAb binding regions are highlighted with colored circles as follows: red circles, J6.36 and J6.103;
purple circle, H77.39; light-blue circles, H77.16; green circle, J6.27; pink circle, H77.31; orange circle, H77.28; yellow circle, H77.56. (C) Summary
of neutralizing MAbs described in this study. EC50 values (neutralization against homologous virus), cross-reactivity to E2 from different genotypes,
inhibition of binding to CD81 and SR-B1, reactivity with different regions of E2, and loss-of-binding residues are listed. MAb names are color
coded to correspond to panels A and B.
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occupancy for neutralization (43, 52, 60, 63, 66). Indeed, our
three most potent MAbs, H77.16, H77.39, and J6.36, neutral-
ized infection in the postattachment assay. Nevertheless,
J6.103 shared apparent binding epitopes with J6.36 yet did not
neutralize efficiently when added after attachment. This dis-
crepancy may be explained by J6.36 having additional amino
acid contacts not identified in our study.
MAb binding to conserved residues may not directly predict
cross-binding or cross-neutralizing capabilities (8, 59). Despite
mapping to highly conserved residues, MAbs H77.31, J.36, and
J6.103 failed to cross-react with any other strains tested, and
J6.27 was cross-reactive with only two of the strains tested. In
comparison, MAb H77.16 was highly cross-reactive but still did
not neutralize heterologous strains. In contrast, H77.39 cross-
reacted with genotypes 1 to 6 and neutralized chimeric virus
representative of all strains except genotype 6. The inability of
H77.39 to neutralize the genotype 6 chimeric virus may be
explained by the presence of a mutation in one of the recog-
nition residues, N417T (24). This mutation is rare in natural
HCV isolates (11, 48) but was required for adaptation of the
HK6a/JFH1 chimera in vitro (24). Mutations at N415 are rare
(11, 48) and attenuating in the context of HCV infection (19).
Generation of an HCV vaccine has been impeded by the
lack of a structural understanding of the epitopes on E2 that
should be targeted by inhibitory antibodies. Although direct
structural confirmation is necessary, our data suggest the exis-
tence of discontinuous epitopes that are recognized by anti-
bodies that inhibit CD81 and SR-B1 binding. The yeast surface
display antibody-mapping data also provide support for a re-
cently proposed structural model of E2 in which the residues
comprising the CD81 binding region lie within a single do-
main of -pleated sheets that contains HVR1 as an N-ter-
minal extension (36). The epitopes defined by the MAbs
H77.16, J6.36, and J6.103 suggest that HVR1 might lie in
proximity to this domain, creating a conformational epitope
(Fig. 8B) that could be a useful target for vaccines and
therapeutic antibodies.
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